International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 8, Issue 5 (September-October 2026) Submit your research before last 3 days of October to publish your research paper in the issue of September-October.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 8 Issue 5
September-October 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

A Comprehensive Review on Stem Cell Therapy and CRISPR/Cas Technology in the Treatment of Thalassemia

Author(s) Ms. Shreya Nair
Country India
Abstract Thalassemia is a widespread hereditary blood disorder, characterized by defective or impaired production of the ???? or ????-globin chains that make up hemoglobin. This imbalance leads to ineffective erythropoiesis, anemia and additional associated symptoms. Current therapeutic strategies largely rely on hematopoietic stem cell (HSC) transplantation as a curative approach. However, recent research illustrates the use of stem cell therapy and CRISPR/Cas gene editing technology as alternative treatment options. Beyond HSCs, mesenchymal stem cells (MSCs) can potentially ameliorate clinical manifestations due to their ability to differentiate into diverse cell types, while induced pluripotent stem cells (iPSCs) are re-engineered somatic cells that can be genetically modified for thalassemia treatment. Advances in clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) include the reactivation of fetal hemoglobin through editing of the erythroid-specific enhancer of BCL11A, direct correction of HBB mutations, and genetic alterations in iPSCs. This review synthesizes a variety of research, examining the therapeutic potential of stem cell therapy and CRISPR/Cas technology in the treatment of thalassemia.
Keywords Thalassemia, Hematopoietic stem cell transplantation, Mesenchymal stem cells, CRISPR/Cas9, BCL11A disruption, HBB gene correction, Induced pluripotent stem cells
Field Biology > Genetics / Molecular
Published In Volume 8, Issue 5, September-October 2026
Published On 2026-09-26
DOI https://doi.org/10.36948/ijfmr.2026.v08i05.88430
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI prefix of IJFMR is 10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com
Powered by Sky Research Publication and Journals